S13 Ep17: 42nd Annual Miami Breast Cancer Conference® Podcast: OncLive On Air CE, Powered by PER

Episode DescriptionIn this podcast, expert Hope Rugo, MD, discusses her approach to treating patients with hormone receptor–positive/HER2-negative breast cancer from the early-stage to metastatic disease. Consideration of these complex clinical scenarios taken from tumor board discussions at the 42nd Annual Miami Breast Cancer Conference® highlight evolving strategies in breast cancer care and clinical decision-making.Acknowledgment of Educational Grant SupportThis activity is supported by educational grants from Exact Sciences Corporation; Lilly; Merck & Co, Inc; Novartis; PreludeDx; Puma Biotechnology, Inc; and Varian Medical Systems, Inc.Today’s faculty is:Hope S. Rugo, MD, FASCODirector, Women’s Cancers Program Division Chief, Breast Medical OncologyProfessor, Department of Medical Oncology & Therapeutics ResearchCity of Hope Comprehensive Cancer CenterDuarte, CAProfessor Emeritus, UCSFDisclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co, Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris.The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.Release DateJune 20, 2025Expiration DateJune 20, 2026